Skip to main content

Table 1 Baseline characteristics of the patients with pseudolithiasis

From: Ceftriaxone-associated pseudolithiasis in hemodialysis patients: a case series study

Patient Age/sex Duration of dialysis after starting ceftriaxone (days)a BMI Primary disease/comorbidity Infection site CVD Fasting Bed-bound Ca-containing drug Serum Alb (g/dL) Adjusted serum Ca (mg/dL) Int-PTH (pg/mL)
1 85/F 1170 14.7 MPA Lung + 1.4 10.4 48
2 82/M 1215 18.9 DM Unknown + + 3.0 8.8 87
3 83/F −1a 20.6 DM Lung + + 2.7 8.8 365
4 71/F 2469 26.7 DM Lung + + 3.4 10.7 163
5 68/M 20 18.4 SLE Lung + 1.8 9.6 81
6 83/M 928 18.1 DM Lung + + + 3.0 9.5 132
7 65/M −2a 27.9 IRGN Lung, penile abscess 2.0 9.7
8 85/M 8 16.2 Unknown/CO2 narcosis Lung + 3.1 8.9 252
9 32/F 868 17.6 FSGS Lung 3.5 9.5 113
10 82/M 0 19.6 DM Lung + 3.7 9.1 69
11 70/M 1065 20.2 CGN/spinal cord injury Lung + 2.8 8.8 116
  1. Alb Albumin, BMI Body mass index, Ca Calcium, CGN Chronic glomerulonephritis, CVD Cerebrovascular disease, DM Diabetes mellitus, FSGS Focal segmental glomerulonephritis, Int-PTH Intact parathormone, IRGN Infection-related glomerulonephritis, SLE Systemic lupus erythematosus, MPA Microscopic polyangiitis, M Male, F Female
  2. aPatients 3 and 7 started receiving ceftriaxone 1 and 2 days, respectively, before initiation of hemodialysis; thus, these numbers are shown as negative
\